• ArQule Provides Clinical Update on ARQ 197 Enrollment completed in Phase 2 trial in non-small cell lung cancer; – Press Releases – CNBC.com
    Approximately 160 patients were enrolled in the NSCLC trial, which is a randomized, double-blind trial comparing combination therapy with ARQ 197 and erlotinib against erlotinib and placebo in EGFR (epidermal growth factor receptor) inhibitor-naive patients in second and third line settings, with the primary endpoint being progression-free survival. Final data from this trial is expected to be available in the first half of 2010.
    (tags: ARQ-197 nsclc c-MET EGFR erlotinib)